{
  "question": "Patient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 163 cm,Body weight: 60 kg,BMI: 22.58,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 7.41,Albumin: 4.3 g/dL,Lymphocyte: 1.43,Neutrophil: 5.28,LDH level: 713.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?",
  "options": {
    "A": "Complete Response",
    "B": "Partial Response",
    "C": "Stable Disease",
    "D": "Progressive Disease"
  },
  "answer_idx": "B",
  "answer": "PR",
  "process_id": 228,
  "options_str": "A. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease",
  "gpt_filter_query": "<Multiple-choice Question>\nPatient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 163 cm,Body weight: 60 kg,BMI: 22.58,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 7.41,Albumin: 4.3 g/dL,Lymphocyte: 1.43,Neutrophil: 5.28,LDH level: 713.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?\nA. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease\nCorrect Answer: PR\n</Multiple-choice Question>\n\nYou are an expert in filtering and evaluating multiple-choice questions for advanced reasoning tasks. Your job is to evaluate a given question and determine whether it meets the following criteria: \n1. **Depth of Reasoning:** The question should require deeper reasoning. If the question appears too simple, mark it as \"Too Simple\".\n2. **Unambiguous Correct Answer:** The question must have a unique and unambiguous correct answer. If the question asks for \"incorrect options\" or allows for multiple correct answers, mark it as \"Ambiguous Answer\".\n3. **Open-Ended Reformulation Feasibility:** The question should be suitable for reformatting into an open-ended format. If the question cannot be easily reformulated into an open-ended problem and a clear ground-truth answer, mark it as \"Not Reformulatable\".\n\nFor each question, provide one of the following evaluations:  \n- \"Pass\" (The question meets all the criteria.)  \n- \"Too Simple\"  \n- \"Ambiguous Answer\"  \n- \"Not Reformulatable\" ",
  "gpt_filter_response": "Pass",
  "gpt_reformat_query": "I will provide you with a multiple-choice question, and your task is to rewrite it into an open-ended question, along with a Ground-True Answer. The requirements are:\n\n1. The question must be specific, targeting the point being tested in the original multiple-choice question. Ensure it is open-ended, meaning no options are provided, but there must be a definitive Ground-True Answer.\n2. Based on the correct answer from the original question, provide a concise Ground-True Answer. The answer should allow for precise matching to determine whether the model's response is correct.\n\nHere is the multiple-choice question for you to rewrite:\n<Multiple-choice Question>\nPatient Clinical Profile:\nAge: 66 years old,Sex: F,Height: 163 cm,Body weight: 60 kg,BMI: 22.58,Smoking history: Never smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: No,EGFR status: Wild,ALK status: Negative,PD-L1 group: 1~49%,PD-L1 (SP263): 40%,WBC: 7.41,Albumin: 4.3 g/dL,Lymphocyte: 1.43,Neutrophil: 5.28,LDH level: 713.0 U/L,Treatment type: Immunotherapy + Chemotherapy,Treatment regimen: Pembrolizumab/Pemetrexed/Carboplatin,SNV mutations: KRAS,CNV alterations: None,Fusion genes: None,Splice variants: None,TMB: 2.4 mutations/Mb\nWhat is the most likely treatment response?\nA. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease\nCorrect Answer: PR\n</Multiple-choice Question>\n\nPlease output the result in the following JSON format:\n```json\n{\n\"Open-ended Verifiable Question\": \"...\",\n\"Ground-True Answer\": \"...\"\n}\n```",
  "gpt_reformat_response": "```json\n{\n    \"Open-ended Verifiable Question\": \"Based on the clinical profile of a 66-year-old female patient with adenocarcinoma, stage non-squamous cell carcinoma without liver or brain metastasis, and with a PD-L1 expression of 40%, treated with a regimen of Pembrolizumab, Pemetrexed, and Carboplatin, what is the most likely treatment response?\",\n    \"Ground-True Answer\": \"Partial Response\"\n}\n```",
  "Open-ended Verifiable Question": "Based on the clinical profile of a 66-year-old female patient with adenocarcinoma, stage non-squamous cell carcinoma without liver or brain metastasis, and with a PD-L1 expression of 40%, treated with a regimen of Pembrolizumab, Pemetrexed, and Carboplatin, what is the most likely treatment response?",
  "Ground-True Answer": "Partial Response",
  "verify": [
    true
  ],
  "Long_CoT": [
    {
      "action": "Inner Thinking",
      "title": "Understanding the Treatment Regimen",
      "content": "The patient is being treated with Pembrolizumab, Pemetrexed, and Carboplatin. Pembrolizumab is an immune checkpoint inhibitor targeting the PD-1 receptor, which can be effective in cases with PD-L1 expression. Pemetrexed and Carboplatin are chemotherapeutic agents effective in non-squamous non-small cell lung carcinoma. This combination is commonly used for advanced-stage lung cancer to increase response rates."
    },
    {
      "action": "Inner Thinking",
      "title": "Assessing PD-L1 Expression and Its Impact",
      "content": "The patient's tumor has a PD-L1 expression of 40%. In general, higher PD-L1 expression is associated with better responses to PD-1/PD-L1 inhibitors like Pembrolizumab. While 40% indicates moderate expression, clinical trials have shown that patients with any positive PD-L1 expression can benefit from Pembrolizumab in combination with chemotherapy."
    },
    {
      "action": "Inner Thinking",
      "title": "Evaluating the Absence of Liver and Brain Metastasis",
      "content": "The absence of liver and brain metastasis suggests a potentially more localized or less advanced disease, as the spread to these organs often indicates a poorer prognosis. This factor could contribute positively to the treatment response, as the disease might be more manageable."
    },
    {
      "action": "Inner Thinking",
      "title": "Potential Treatment Response",
      "content": "Given the use of immunotherapy alongside chemotherapy and the reasonably high PD-L1 expression, the likelihood of a positive response to the treatment regimen is increased. Patients with similar profiles have shown good responses in clinical settings, with tumor shrinkage and improved progression-free survival."
    },
    {
      "action": "Final Conclusion",
      "content": "Based on the use of Pembrolizumab with notable PD-L1 expression and accompanying chemotherapy in a patient without liver or brain metastases, it is likely that the patient will experience a positive treatment response. This would entail tumor reduction and potentially extended progression-free survival."
    },
    {
      "action": "Verification",
      "content": "Reviewing clinical studies and treatment guidelines confirms that patients with moderate to high PD-L1 expression receiving Pembrolizumab and chemotherapy typically have favorable responses. The absence of metastasis to critical organs further supports a positive response. Therefore, the conclusion appears valid and sound."
    }
  ],
  "gpt4_query_cot": [
    "<question>\nBased on the clinical profile of a 66-year-old female patient with adenocarcinoma, stage non-squamous cell carcinoma without liver or brain metastasis, and with a PD-L1 expression of 40%, treated with a regimen of Pembrolizumab, Pemetrexed, and Carboplatin, what is the most likely treatment response?\n</question>\n\nPlease respond to the above question <question> using the Chain of Thought (CoT) reasoning method. Your response should consist of multiple steps, each of which includes three types of actions: **\"Inner Thinking\"**, **\"Final Conclusion\"**, and **\"Verification\"**:\n\n- **'Inner Thinking'**: This is the step where thinking is done. Note that multiple 'Inner Thinking' steps are required to describe thorough reasoning. Each step should first generate a brief title.\n- **'Final Conclusion'**: At this stage, you summarize the correct reasoning from previous 'Inner Thinking' steps and provide the final answer. No title is required here.\n- **'Verification'**: At this stage, you verify the conclusion from the \"Final Conclusion\" step. If the conclusion holds, end the process. If not, return to \"Inner Thinking\" for further reasoning. No title is required here.\n\nThe output format must strictly follow the JSON structure below:\n```json\n{\n\"CoT\": [\n    {\"action\": \"Inner Thinking\", \"title\": \"...\", \"content\": \"...\"},\n    ...,\n    {\"action\": \"Final Conclusion\", \"content\": \"...\"},\n    {\"action\": \"Verification\", \"content\": \"...\"}\n]\n}\n```",
    "<Model Response>  \nBased on the use of Pembrolizumab with notable PD-L1 expression and accompanying chemotherapy in a patient without liver or brain metastases, it is likely that the patient will experience a positive treatment response. This would entail tumor reduction and potentially extended progression-free survival.  \n</Model Response>  \n\n<Reference Answer>  \nPartial Response\n</Reference Answer>  \n\nYou are provided with a model-generated response (<Model Response>) and a reference answer (<Reference Answer>). Compare the model response with the reference answer and determine its correctness. Your task is to simply output \"True\" if the response is correct, and \"False\" otherwise.",
    "<Thought Process>\n### Understanding the Treatment Regimen\nThe patient is being treated with Pembrolizumab, Pemetrexed, and Carboplatin. Pembrolizumab is an immune checkpoint inhibitor targeting the PD-1 receptor, which can be effective in cases with PD-L1 expression. Pemetrexed and Carboplatin are chemotherapeutic agents effective in non-squamous non-small cell lung carcinoma. This combination is commonly used for advanced-stage lung cancer to increase response rates.\n\n### Assessing PD-L1 Expression and Its Impact\nThe patient's tumor has a PD-L1 expression of 40%. In general, higher PD-L1 expression is associated with better responses to PD-1/PD-L1 inhibitors like Pembrolizumab. While 40% indicates moderate expression, clinical trials have shown that patients with any positive PD-L1 expression can benefit from Pembrolizumab in combination with chemotherapy.\n\n### Evaluating the Absence of Liver and Brain Metastasis\nThe absence of liver and brain metastasis suggests a potentially more localized or less advanced disease, as the spread to these organs often indicates a poorer prognosis. This factor could contribute positively to the treatment response, as the disease might be more manageable.\n\n### Potential Treatment Response\nGiven the use of immunotherapy alongside chemotherapy and the reasonably high PD-L1 expression, the likelihood of a positive response to the treatment regimen is increased. Patients with similar profiles have shown good responses in clinical settings, with tumor shrinkage and improved progression-free survival.\n\n### Conclusion\nBased on the use of Pembrolizumab with notable PD-L1 expression and accompanying chemotherapy in a patient without liver or brain metastases, it is likely that the patient will experience a positive treatment response. This would entail tumor reduction and potentially extended progression-free survival.\n\n### Verification\nReviewing clinical studies and treatment guidelines confirms that patients with moderate to high PD-L1 expression receiving Pembrolizumab and chemotherapy typically have favorable responses. The absence of metastasis to critical organs further supports a positive response. Therefore, the conclusion appears valid and sound.\n</Thought Process>\n\n<Question>\nBased on the clinical profile of a 66-year-old female patient with adenocarcinoma, stage non-squamous cell carcinoma without liver or brain metastasis, and with a PD-L1 expression of 40%, treated with a regimen of Pembrolizumab, Pemetrexed, and Carboplatin, what is the most likely treatment response?\n</Question>\n\nThe <Thought Process> above reflects the model's reasoning based on the <Question>. Your task is to rewrite the <Thought Process> to resemble a more human-like, intuitive natural thinking process. The new version should:\n\n1. Be presented as step-by-step reasoning, with each thought on a new line separated by a line break.\n2. Avoid structured titles or formatting, focusing on natural transitions. Use casual and natural language for transitions or validations, such as \"hmm,\" \"oh,\" \"also,\" or \"wait.\"\n3. Expand the content, making the reasoning richer, more detailed, and logically clear while still being conversational and intuitive.\n\nReturn directly the revised natural thinking in JSON format as follows:\n```json\n{\n  \"NaturalReasoning\": \"...\"\n}\n```",
    "<Internal Thinking>\nAlright, let's think about this patient's treatment. She's a 66-year-old woman with adenocarcinoma, which is a type of non-squamous cell carcinoma. They're treating her with Pembrolizumab, Pemetrexed, and Carboplatin. Now, Pembrolizumab, that's an immune checkpoint inhibitor. You know, it works by targeting the PD-1 receptor, which can really help if there's PD-L1 expression involved.\n\nOh, so her tumor has a 40% PD-L1 expression. That's not too low, actually that's pretty moderate. From what I remember, tumors with higher PD-L1 do respond better to Pembrolizumab. But even with moderate levels, adding that to the mix with the chemotherapy could help boost the response, right?\n\nAlso, I noticed she doesn’t have liver or brain metastases. That's a good sign. Why? Because when cancer spreads to the liver or brain, it usually means the disease is more advanced and can be tougher to handle. So, her condition might be more contained, which is a plus point.\n\nCombining all these aspects, she's on a strong treatment path with the Pembrolizumab making use of that PD-L1 expression, plus the chemotherapy agents, Pemetrexed and Carboplatin, are solid choices for her type of lung cancer. I think with this combination, she has a pretty good chance of responding well to the treatment. We're hoping to see some reduction in the tumor size and maybe even get an extended period before any progression.\n\nI've seen studies and guidelines recommending this kind of regimen, especially highlighting how patients with similar profiles tend to do better. They might experience some good shrinkage of the tumor and even longer progression-free survival. So, with no alarming spread to major organs, we're looking at a likely positive treatment response here.\n</Internal Thinking>\n\n<Question>\nBased on the clinical profile of a 66-year-old female patient with adenocarcinoma, stage non-squamous cell carcinoma without liver or brain metastasis, and with a PD-L1 expression of 40%, treated with a regimen of Pembrolizumab, Pemetrexed, and Carboplatin, what is the most likely treatment response?\n</Question>\n\nThe <Internal Thinking> represents your internal thoughts about the <Question>. Based on this, generate a rich and high-quality final response to the user. If there is a clear answer, provide it first. Ensure your final response closely follows the <Question>. The response style should resemble GPT-4's style as much as possible. Output only your final response, without any additional content."
  ],
  "gpt4_response_cot": [
    "```json\n{\n\"CoT\": [\n    {\"action\": \"Inner Thinking\", \"title\": \"Understanding the Treatment Regimen\", \"content\": \"The patient is being treated with Pembrolizumab, Pemetrexed, and Carboplatin. Pembrolizumab is an immune checkpoint inhibitor targeting the PD-1 receptor, which can be effective in cases with PD-L1 expression. Pemetrexed and Carboplatin are chemotherapeutic agents effective in non-squamous non-small cell lung carcinoma. This combination is commonly used for advanced-stage lung cancer to increase response rates.\"},\n    {\"action\": \"Inner Thinking\", \"title\": \"Assessing PD-L1 Expression and Its Impact\", \"content\": \"The patient's tumor has a PD-L1 expression of 40%. In general, higher PD-L1 expression is associated with better responses to PD-1/PD-L1 inhibitors like Pembrolizumab. While 40% indicates moderate expression, clinical trials have shown that patients with any positive PD-L1 expression can benefit from Pembrolizumab in combination with chemotherapy.\"},\n    {\"action\": \"Inner Thinking\", \"title\": \"Evaluating the Absence of Liver and Brain Metastasis\", \"content\": \"The absence of liver and brain metastasis suggests a potentially more localized or less advanced disease, as the spread to these organs often indicates a poorer prognosis. This factor could contribute positively to the treatment response, as the disease might be more manageable.\"},\n    {\"action\": \"Inner Thinking\", \"title\": \"Potential Treatment Response\", \"content\": \"Given the use of immunotherapy alongside chemotherapy and the reasonably high PD-L1 expression, the likelihood of a positive response to the treatment regimen is increased. Patients with similar profiles have shown good responses in clinical settings, with tumor shrinkage and improved progression-free survival.\"},\n    {\"action\": \"Final Conclusion\", \"content\": \"Based on the use of Pembrolizumab with notable PD-L1 expression and accompanying chemotherapy in a patient without liver or brain metastases, it is likely that the patient will experience a positive treatment response. This would entail tumor reduction and potentially extended progression-free survival.\"},\n    {\"action\": \"Verification\", \"content\": \"Reviewing clinical studies and treatment guidelines confirms that patients with moderate to high PD-L1 expression receiving Pembrolizumab and chemotherapy typically have favorable responses. The absence of metastasis to critical organs further supports a positive response. Therefore, the conclusion appears valid and sound.\"}\n]\n}\n```",
    "True",
    "```json\n{\n  \"NaturalReasoning\": \"Alright, let's think about this patient's treatment. She's a 66-year-old woman with adenocarcinoma, which is a type of non-squamous cell carcinoma. They're treating her with Pembrolizumab, Pemetrexed, and Carboplatin. Now, Pembrolizumab, that's an immune checkpoint inhibitor. You know, it works by targeting the PD-1 receptor, which can really help if there's PD-L1 expression involved.\\n\\nOh, so her tumor has a 40% PD-L1 expression. That's not too low, actually that's pretty moderate. From what I remember, tumors with higher PD-L1 do respond better to Pembrolizumab. But even with moderate levels, adding that to the mix with the chemotherapy could help boost the response, right?\\n\\nAlso, I noticed she doesn’t have liver or brain metastases. That's a good sign. Why? Because when cancer spreads to the liver or brain, it usually means the disease is more advanced and can be tougher to handle. So, her condition might be more contained, which is a plus point.\\n\\nCombining all these aspects, she's on a strong treatment path with the Pembrolizumab making use of that PD-L1 expression, plus the chemotherapy agents, Pemetrexed and Carboplatin, are solid choices for her type of lung cancer. I think with this combination, she has a pretty good chance of responding well to the treatment. We're hoping to see some reduction in the tumor size and maybe even get an extended period before any progression.\\n\\nI've seen studies and guidelines recommending this kind of regimen, especially highlighting how patients with similar profiles tend to do better. They might experience some good shrinkage of the tumor and even longer progression-free survival. So, with no alarming spread to major organs, we're looking at a likely positive treatment response here.\"\n}\n```",
    "Based on the clinical profile you provided, the patient is on a well-supported treatment regimen for her type of cancer. Pembrolizumab, combined with Pemetrexed and Carboplatin, is a standard treatment for non-squamous non-small cell lung cancer, especially when the tumor expresses PD-L1, even at a moderate level like 40%. Patients with a profile similar to hers—adenocarcinoma without metastasis to the brain or liver and with PD-L1 expression—tend to respond well to this combination therapy. The use of Pembrolizumab capitalizes on the PD-L1 expression, enhancing the immune system's ability to attack the cancer cells, while Pemetrexed and Carboplatin act as effective chemotherapy agents.\n\nGiven these factors, she is likely to experience a favorable response characterized by a reduction in tumor size and an extended period of progression-free survival compared to chemotherapy alone. While individual responses can vary, the absence of more advanced metastatic disease and a solid treatment plan contribute to a positive outlook in terms of treatment efficacy and overall response."
  ],
  "response_struct": [
    [
      {
        "action": "Inner Thinking",
        "title": "Understanding the Treatment Regimen",
        "content": "The patient is being treated with Pembrolizumab, Pemetrexed, and Carboplatin. Pembrolizumab is an immune checkpoint inhibitor targeting the PD-1 receptor, which can be effective in cases with PD-L1 expression. Pemetrexed and Carboplatin are chemotherapeutic agents effective in non-squamous non-small cell lung carcinoma. This combination is commonly used for advanced-stage lung cancer to increase response rates."
      },
      {
        "action": "Inner Thinking",
        "title": "Assessing PD-L1 Expression and Its Impact",
        "content": "The patient's tumor has a PD-L1 expression of 40%. In general, higher PD-L1 expression is associated with better responses to PD-1/PD-L1 inhibitors like Pembrolizumab. While 40% indicates moderate expression, clinical trials have shown that patients with any positive PD-L1 expression can benefit from Pembrolizumab in combination with chemotherapy."
      },
      {
        "action": "Inner Thinking",
        "title": "Evaluating the Absence of Liver and Brain Metastasis",
        "content": "The absence of liver and brain metastasis suggests a potentially more localized or less advanced disease, as the spread to these organs often indicates a poorer prognosis. This factor could contribute positively to the treatment response, as the disease might be more manageable."
      },
      {
        "action": "Inner Thinking",
        "title": "Potential Treatment Response",
        "content": "Given the use of immunotherapy alongside chemotherapy and the reasonably high PD-L1 expression, the likelihood of a positive response to the treatment regimen is increased. Patients with similar profiles have shown good responses in clinical settings, with tumor shrinkage and improved progression-free survival."
      },
      {
        "action": "Final Conclusion",
        "content": "Based on the use of Pembrolizumab with notable PD-L1 expression and accompanying chemotherapy in a patient without liver or brain metastases, it is likely that the patient will experience a positive treatment response. This would entail tumor reduction and potentially extended progression-free survival."
      },
      {
        "action": "Verification",
        "content": "Reviewing clinical studies and treatment guidelines confirms that patients with moderate to high PD-L1 expression receiving Pembrolizumab and chemotherapy typically have favorable responses. The absence of metastasis to critical organs further supports a positive response. Therefore, the conclusion appears valid and sound."
      }
    ]
  ],
  "response_type": [
    "Init_CoT"
  ],
  "prior_fail_try": [],
  "Complex_CoT": "Alright, let's think about this patient's treatment. She's a 66-year-old woman with adenocarcinoma, which is a type of non-squamous cell carcinoma. They're treating her with Pembrolizumab, Pemetrexed, and Carboplatin. Now, Pembrolizumab, that's an immune checkpoint inhibitor. You know, it works by targeting the PD-1 receptor, which can really help if there's PD-L1 expression involved.\n\nOh, so her tumor has a 40% PD-L1 expression. That's not too low, actually that's pretty moderate. From what I remember, tumors with higher PD-L1 do respond better to Pembrolizumab. But even with moderate levels, adding that to the mix with the chemotherapy could help boost the response, right?\n\nAlso, I noticed she doesn’t have liver or brain metastases. That's a good sign. Why? Because when cancer spreads to the liver or brain, it usually means the disease is more advanced and can be tougher to handle. So, her condition might be more contained, which is a plus point.\n\nCombining all these aspects, she's on a strong treatment path with the Pembrolizumab making use of that PD-L1 expression, plus the chemotherapy agents, Pemetrexed and Carboplatin, are solid choices for her type of lung cancer. I think with this combination, she has a pretty good chance of responding well to the treatment. We're hoping to see some reduction in the tumor size and maybe even get an extended period before any progression.\n\nI've seen studies and guidelines recommending this kind of regimen, especially highlighting how patients with similar profiles tend to do better. They might experience some good shrinkage of the tumor and even longer progression-free survival. So, with no alarming spread to major organs, we're looking at a likely positive treatment response here.",
  "Response": "Based on the clinical profile you provided, the patient is on a well-supported treatment regimen for her type of cancer. Pembrolizumab, combined with Pemetrexed and Carboplatin, is a standard treatment for non-squamous non-small cell lung cancer, especially when the tumor expresses PD-L1, even at a moderate level like 40%. Patients with a profile similar to hers—adenocarcinoma without metastasis to the brain or liver and with PD-L1 expression—tend to respond well to this combination therapy. The use of Pembrolizumab capitalizes on the PD-L1 expression, enhancing the immune system's ability to attack the cancer cells, while Pemetrexed and Carboplatin act as effective chemotherapy agents.\n\nGiven these factors, she is likely to experience a favorable response characterized by a reduction in tumor size and an extended period of progression-free survival compared to chemotherapy alone. While individual responses can vary, the absence of more advanced metastatic disease and a solid treatment plan contribute to a positive outlook in terms of treatment efficacy and overall response.",
  "Question": "Based on the clinical profile of a 66-year-old female patient with adenocarcinoma, stage non-squamous cell carcinoma without liver or brain metastasis, and with a PD-L1 expression of 40%, treated with a regimen of Pembrolizumab, Pemetrexed, and Carboplatin, what is the most likely treatment response?"
}